

## **Invitation to presentation of Cantargia's report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST**

**Cantargia AB will publish the company's report for the first quarter of 2023 on Tuesday, May 23, 2023 at 08:30 a.m. CEST.**

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 23, at 10:00 a.m. CEST, where the company management will present Cantargia and comment on the quarterly report for the first quarter 2023, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: <https://ir.financialhearings.com/cantargia-q1-2023>

If you wish to participate via teleconference, please register via the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://conference.financialhearings.com/teleconference/?id=200784>

The webcast will also be available on demand on Cantargia's corporate website: [www.cantargia.com](http://www.cantargia.com).

### **Contact**

Göran Forsberg, CEO

Telephone: +46 (0)46-275 62 60

E-mail: [goran.forsberg@cantargia.com](mailto:goran.forsberg@cantargia.com)

### **About Cantargia**

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune /inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at [www.cantargia.com](http://www.cantargia.com).



**PRESS RELEASE**

09 May 2023 11:30:00 CEST

**Attachments**

**Invitation to presentation of Cantargia's report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST**